![]() |
市場調査レポート
商品コード
1697980
放出制御ドラッグデリバリー市場- 世界の産業規模、シェア、動向、機会、予測、技術別、放出メカニズム別、用途別、地域別、競合別セグメント、2020-2030FControlled Release Drug Delivery Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Release Mechanism, By Application, By Region and Competition, 2020-2030F |
||||||
カスタマイズ可能
|
放出制御ドラッグデリバリー市場- 世界の産業規模、シェア、動向、機会、予測、技術別、放出メカニズム別、用途別、地域別、競合別セグメント、2020-2030F |
出版日: 2025年03月28日
発行: TechSci Research
ページ情報: 英文 186 Pages
納期: 2~3営業日
|
放出制御ドラッグデリバリーの世界市場規模は2024年に562億4,000万米ドルで、予測期間には1,037億5,000万米ドルに達すると予測され、2030年までのCAGRは10.72%です。
放出制御ドラッグデリバリー市場は、製薬会社が薬剤の有効性と患者のコンプライアンスを高めることにますます注力するようになり、拡大しています。放出制御ドラッグデリバリーシステムは、長期間にわたって薬剤を徐々に放出することで、投与回数を減らし、副作用を最小限に抑えることを可能にします。精密医療や治療成績を向上させる持続性製剤に対する需要の高まりにより、同市場は力強い成長を遂げています。主要企業は、薬物放出メカニズムを最適化するために、先端ポリマー技術、ナノテクノロジーに基づくデリバリーシステム、生分解性インプラントに投資しています。心血管障害、糖尿病、神経疾患などの慢性疾患の有病率の増加は、制御放出製剤が治療のアドヒアランスを改善することから、さらに普及を促進しています。
市場概要 | |
---|---|
予測期間 | 2026-2030 |
市場規模:2024年 | 562億4,000万米ドル |
市場規模:2030年 | 1,037億5,000万米ドル |
CAGR:2025年~2030年 | 10.72% |
急成長セグメント | ターゲット・デリバリー |
最大市場 | 北米 |
同市場は、ドラッグの製剤化とデリバリー・システムの技術的進歩により、より効率的で的を絞った治療が可能になっています。ミクロスフェア、リポソーム、経皮パッチなどの技術革新により、薬物のバイオアベイラビリティと安定性が向上しています。製薬会社は、特に複雑な生物製剤や遺伝子治療薬の放出制御製剤の開発を加速させるため、戦略的提携を積極的に模索しています。ヘルスケア支出の増加と新規ドラッグデリバリー法に対する規制当局の好意的なサポートが市場拡大を促進しています。患者中心のソリューションに対する需要が業界動向を形成しており、経口剤、注射剤、埋め込み型のドラッグデリバリーシステムが広く受け入れられています。バイオ医薬品と個別化医療の急増は有利な機会をもたらし、高度な薬剤カプセル化技術のさらなる研究開発を促しています。
慢性疾患の増加
規制上のハードルと承認の遅れ
生分解性および移植可能ドラッグデリバリーシステム
Global Controlled Release Drug Delivery Market was valued at USD 56.24 Billion in 2024 and is expected to reach USD 103.75 Billion in the forecast period with a CAGR of 10.72% through 2030. The controlled release drug delivery market is expanding as pharmaceutical companies increasingly focus on enhancing drug efficacy and patient compliance. This system enables the gradual release of drugs over an extended period, reducing dosing frequency and minimizing side effects. The market is witnessing strong growth due to rising demand for precision medicine and sustained drug formulations that improve therapeutic outcomes. Key players are investing in advanced polymer technologies, nanotechnology-based delivery systems, and biodegradable implants to optimize drug release mechanisms. The increasing prevalence of chronic diseases such as cardiovascular disorders, diabetes, and neurological conditions is further driving adoption, as controlled release formulations offer improved treatment adherence.
Market Overview | |
---|---|
Forecast Period | 2026-2030 |
Market Size 2024 | USD 56.24 Billion |
Market Size 2030 | USD 103.75 Billion |
CAGR 2025-2030 | 10.72% |
Fastest Growing Segment | Targeted Delivery |
Largest Market | North America |
The market benefits from technological advancements in drug formulation and delivery systems, enabling more efficient and targeted therapies. Innovations in microspheres, liposomes, and transdermal patches are enhancing drug bioavailability and stability. Pharmaceutical companies are actively seeking strategic collaborations to accelerate the development of controlled release formulations, particularly for complex biologics and gene therapies. Rising healthcare expenditure and favorable regulatory support for novel drug delivery methods are fostering market expansion. Demand for patient-centric solutions is shaping industry trends, with oral, injectable, and implantable drug delivery systems gaining widespread acceptance. The surge in biopharmaceuticals and personalized medicine presents lucrative opportunities, encouraging further research and development in advanced drug encapsulation techniques.
Key Market Drivers
Increasing Prevalence of Chronic Diseases
The global incidence of chronic diseases such as diabetes, cardiovascular diseases, cancer, and respiratory disorders continues to rise. According to the World Health Organization (WHO), cardiovascular diseases accounted for approximately 19 million deaths in 2021, cancers for 10 million, chronic respiratory diseases for 4 million, and diabetes for over 2 million, including deaths from kidney disease caused by diabetes. This increase is largely attributed to factors such as sedentary lifestyles, poor dietary habits, and an aging population. Notably, the number of people living with diabetes surged from 200 million in 1990 to 830 million in 2022, with prevalence rising more rapidly in low- and middle-income countries.
Managing chronic diseases often necessitates long-term medication regimens, which can be challenging for patients to adhere to consistently. Studies have shown that approximately 50% of patients with chronic conditions demonstrate poor medication adherence, leading to suboptimal health outcomes and increased healthcare costs.
Key Market Challenges
Regulatory Hurdles and Approval Delays
Stringent Regulatory Requirements: Developing and gaining regulatory approval for controlled release drug delivery systems involves navigating complex and stringent regulatory pathways. Regulatory agencies, such as the FDA (U.S. Food and Drug Administration) and the EMA (European Medicines Agency), have rigorous requirements to ensure the safety and efficacy of these systems.
The regulatory approval process can be lengthy and resource-intensive, significantly delaying the market entry of new controlled release products. This can discourage investment and slow down market growth. Regulatory requirements and guidelines for drug delivery systems may evolve over time, necessitating costly adjustments to meet updated standards.
Key Market Trends
Biodegradable and Implantable Drug Delivery Systems
Growing environmental awareness and sustainability concerns have prompted the development of biodegradable drug delivery systems. These systems are designed to gradually release drugs while breaking down harmlessly in the body, reducing waste and environmental impact.
Implantable controlled release systems, such as biodegradable implants, are gaining prominence for delivering long-lasting therapeutics. They offer convenience for patients by eliminating the need for frequent dosing and provide sustained drug release over extended periods. Biodegradable and implantable systems are particularly valuable in treating chronic conditions, as they can provide continuous drug delivery, potentially improving patient compliance and therapeutic outcomes.
In this report, the Global Controlled Release Drug Delivery Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Controlled Release Drug Delivery Market.
Global Controlled Release Drug Delivery market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: